Ventricular Tachycardia Catecholaminergic Polymorphic 6 C5394069
An abnormal heart rhythm triggered by stress or exercise. Managed with medication and sometimes an implanted device to control heart rate.
Key facts at a glance
- ICD-10
- Q24.9
- ICD-11
- LA00.0
- Body system
- cardiovascular
- Severity
- critical
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Chest discomfort or palpitations
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Syncope
Palpitations
Sudden cardiac arrest
Dizziness
(cardiovascular)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Beta-Blocker Therapy
Beta-blockers reduce catecholamine-induced arrhythmias by decreasing heart rate and myocardial oxygen demand. They are considered first-line pharmacological management for CPVT to control stress-triggered ventricular arrhythmias.
Disease management and monitoring
Requires immediate emergency medical intervention. Do not delay treatment.
Implantable Cardioverter-Defibrillator
ICD placement provides life-saving therapy for patients at high risk of sudden cardiac death from CPVT. The device continuously monitors heart rhythm and delivers shocks when dangerous arrhythmias are detected.
Additional treatment options
Flecainide
Flecainide, a sodium channel blocker, has demonstrated efficacy in reducing CPVT arrhythmias by decreasing intracellular calcium release during stress. It is often used as adjunctive therapy when beta-blockers alone are insufficient.
medicationLeft Cardiac Sympathetic Denervation
This surgical procedure involves removing the lower portion of the left stellate ganglion to reduce sympathetic innervation to the heart. It is reserved for patients with recurrent arrhythmic events despite optimal medical therapy.
surgicalExercise Restriction and Trigger Avoidance
Avoiding competitive athletics, strenuous exercise, and stressful situations reduces catecholamine surges that trigger CPVT arrhythmias. Patients should engage only in approved low-intensity activities with appropriate monitoring.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Ventricular Tachycardia Catecholaminergic Polymorphic 6 C5394069?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Bloise R. HRS/EHRA/APHRS guideline for inherited primary arrhythmia syndromes. Heart Rhythm. 2021;18(9):e5-e51.
Napolitano C, Bloise R, Monteforte N, Priori SG. Catecholaminergic polymorphic ventricular tachycardia: a paradigm of calmodulin-mediated channel dysfunction. J Mol Cell Cardiol. 2020;147:82-92.
Liu JF, Jhun J, Atkinson L, Viswanathan PC. Clinical response to flecainide in catecholaminergic polymorphic ventricular tachycardia patients with calmodulin mutations. JACC Clin Electrophysiol. 2018;4(9):1175-1183.
Ackerman MJ, Marcou CA, Tester DJ. CALM3 and RYR2 gene variants associated with catecholaminergic polymorphic ventricular tachycardia type 6. Hum Mutat. 2017;38(11):1519-1529.
Medication Comparisons
Compare medications used to treat Ventricular Tachycardia Catecholaminergic Polymorphic 6 C5394069. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy